API Efavirenz

Efavirenz More Info

Efavirenz is a non - nucleoside reverse transcriptase inhibitor (NNRTI) primarily used in the treatment of human immunodeficiency virus type 1 (HIV - 1) infection. It plays a vital role in combined antiretroviral therapy (cART) regimens, which are the standard of care for managing HIV.

Basic Properties

Chemical Formula: C₁₄H₉ClF₃NO₂

Molecular Weight: 315.68 g/mol

Physical Appearance: It usually exists as a white to slightly yellow crystalline powder. It has low solubility in water but is soluble in organic solvents such as methanol and dimethyl sulfoxide (DMSO).

Mechanism of Action

Efavirenz exerts its antiviral effect by binding non - competitively to the reverse transcriptase enzyme of HIV - 1. This binding blocks the enzyme’s activity, which is essential for the virus to convert its RNA genome into DNA and integrate into the host cell’s genome. By inhibiting this step, Efavirenz prevents HIV replication and reduces the viral load in the body.

Clinical Uses

HIV Treatment

It is used in both adult and pediatric patients (children over 3 years old) with HIV - 1 infection. Typically, it is administered in combination with other antiretroviral drugs (such as nucleoside reverse transcriptase inhibitors, NRTIs) to avoid the development of drug resistance.

Prevention

In some cases, it may be part of pre - exposure prophylaxis (PrEP) regimens for individuals at high risk of HIV infection, though this application requires strict medical supervision.

Dosage and Administration

For adults, the standard oral dose is 600 mg once daily, usually taken at bedtime to minimize central nervous system side effects.

Pediatric dosage is based on body weight, and the drug is available in tablet or oral solution form to suit different patient needs.

Side Effects

Central Nervous System (CNS) Effects

The most common side effects include dizziness, headache, insomnia, vivid dreams, and mood changes (such as anxiety or irritability). These symptoms are usually mild and tend to resolve within the first 2 - 4 weeks of treatment.

Other Common Side Effects

Rash, nausea, diarrhea, and elevated liver enzymes may also occur. Severe rash (such as Stevens - Johnson syndrome) is rare but requires immediate medical attention.

Contraindications and Precautions

Contraindications: Hypersensitivity to efavirenz or any component of the formulation.

Precautions

Liver Function Monitoring: Patients with pre - existing liver disease need regular liver function tests, as Efavirenz may cause liver enzyme elevation.

Pregnancy and Lactation: It is classified as a pregnancy category D drug in some regions; pregnant women should use it only if the benefits outweigh the risks. HIV - positive mothers should not breastfeed to avoid transmitting the virus.

Drug Interactions: Efavirenz is a substrate and inducer of the cytochrome P450 enzyme system, so it may interact with many drugs (such as anticoagulants, anticonvulsants, and other antiretrovirals). A doctor should be consulted before combining medications.

Market Information

Efavirenz is available as both brand - name (e.g., Sustiva) and generic formulations. It is included in the World Health Organization (WHO) Model List of Essential Medicines, making it a key drug for HIV treatment in both developed and developing countries.